PD1+ tumor associated macrophages predict poor prognosis of locally advanced esophageal squamous cell carcinoma
PD1+ tumor associated macrophages predict poor prognosis of locally advanced esophageal squamous cell carcinoma
复制标题
DOI：
10.2217/fon-2019-0519
复制
发表时间：
2019-12-01
期刊：
影响因子：
3.3
通讯作者：
Ding, Gaofeng
中科院分区：
文献类型：
--
作者：
Lu, Yufei;Guo, Leiming;Ding, Gaofeng
目的：肿瘤相关巨噬细胞是最丰富的肿瘤免疫细胞。然而，关于CD68(+)PD1（+）巨噬细胞的身份及其在食管鳞状细胞癌（ESCC）预后中的作用知之甚少。方法与方法：采用免疫荧光、流式细胞术、RT-PCR检测ESCC组织中PD1（+）巨噬细胞。结果：肿瘤组织中表达较高M2标志物的CD68(+)PD1（+）巨噬细胞较癌旁组织增加约4.2倍。此外，PD1（高）巨噬细胞与更多的恶性表型和不良预后显著相关。PD1治疗可增强培养巨噬细胞的吞噬作用，使巨噬细胞重定向为m1样表型。结论：综上所述，CD68(+)PD1（+）巨噬细胞是ESCC肿瘤相关巨噬细胞，可以预测ESCC的预后。
Aim: Tumor associated macrophages are the most abundant cancer immune cells. However, little was known about the identity of CD68(+)PD1(+) macrophages as well as the contributions in the prognosis of esophageal squamous cell carcinoma (ESCC). Methods & methods: Immunofluorescence, flowcytometry and RT-PCR were used to analysis PD1(+) macrophages in ESCC. Results: CD68(+)PD1(+) macrophages which can express higher M2 markers in cancer tissues, increased about 4.2-times compared with para-cancer tissues. Additionally, PD1(high) macrophages were significantly correlated with more malignant phenotypes and poor prognosis. PD1 treatment can enhance phagocytosis of cultured macrophages and redirect this macrophage to M1-like phenotype. Conclusion: Thus, our findings overall indicate that CD68(+)PD1(+) macrophages are tumor associated macrophagess in ESCC, which can forecast the prognosis of ESCC.